Akso Health Group
AHG
6 hedge funds and large institutions have $203K invested in Akso Health Group in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
1.08% more ownership
Funds ownership: 0% → 1.08% (+1.1%)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
37% less capital invested
Capital invested by funds: $323K → $203K (-$120K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$15.5K |
| 2 |
CCG
Catalina Capital Group
Torrance,
California
|
+$15.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$35.7K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$14.3K |
| 3 |
Millennium Management
New York
|
-$10.8K |
AHG Hedge Fund Activity: Q2 2024 in Review
6 of the 6,938 institutional investors tracked by Wall St. Rank reported a position in Akso Health Group (AHG) for Q2 2024, worth a combined $203K — down 37% from $323K a quarter earlier.
Fund positioning in AHG was balanced in Q2 2024: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, adding an estimated $15.5K. The largest seller was Renaissance Technologies, cutting an estimated $35.7K.
- 6 institutional investors held Akso Health Group (AHG) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $203K of Akso Health Group stock for Q2 2024, down 37% quarter-over-quarter.
- 1 fund opened new Akso Health Group positions in Q2 2024 and 1 closed out, a net change of 0 holders.
- The largest Akso Health Group buyer in Q2 2024 was UBS Group, an estimated $15.5K added.
- The largest Akso Health Group seller in Q2 2024 was Renaissance Technologies, an estimated $35.7K sold.
Based on aggregated 13F filings for Q2 2024.